Louise Bowman

Louise Bowman is Professor of Medicine and Clinical Trials at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). Her specialist clinical background is in diabetes and endocrinology. She has particular research interests in cardiovascular disease in diabetes, and maintains her clinical practice with regular specialist lipid clinics.

She is Chief Investigator for the ORION-4 trial which is assessing the effects of inclisiran on clinical outcomes among 15,000 people with atherosclerotic cardiovascular disease, and for the AMALFI trial, which is assessing the value of screening for undiagnosed atrial fibrillation in high-risk individuals. 

Professor Bowman was also Co-principal Investigator for the ASCEND trial, which studied the effects of aspirin and of omega-3 fatty acid supplementation for the primary prevention of cardiovascular disease in 15,000 people with diabetes, and for the REVEAL study, an international clinical trial that assessed the efficacy and safety of the CETP-inhibitor, anacetrapib, in 30,000 high-risk individuals. 

Through her work on large-scale trials in cardiovascular disease she has developed a specialist interest in clinical trials methodology with a particular focus on the development, application and widespread promotion of methods to enhance the design and conduct of trials to ensure high quality outputs and reliable results at low cost. She is Co-Course Director for the MSc in Clinical Trials which is a part-time distance learning course that provides in-depth training in the principles and practice of conducting large-scale, randomised clinical trials.